Abbvie Inc.

Abbott Laboratories Corporation

Other

Kelly Mullen

Andrew Burchat

David J Calderwood

Michael M Friedman

Noel S Wilson

Eric C Breinlinger

David Ihle

Heather M Davis

Anil Vasudevan

Gavin C Hirst

Michael Michaelides

Kristine E Frank

Steven K Davidsen

Paul Rafferty

Michael L Curtin

Robin R Frey

Michael Z Hoemann

Michael Morytko

Howard Robin Heyman

Maria A Argiriadi

Justin D Dietrich

Augustine Osuma

Carol K Wada

Peter Hrnciar

Patrick Betschmann

Melanie A Muckey

Anna M Ericsson

Thomas D Gordon

Neil Wishart

Biqin C Li

Lu Wang

Kevin Patrick Cusack

Gagandeep K Somal

David Andrew Kinsman

Clara I Villamil

Richard W Dixon

Jeffrey W Voss

David Wayne Borhani

Dawn M George

Robert V Talanian

Bruce Clapham

Dominique Bonafoux

Nathan Josephsohn

Lei Wang

Xiaoyun Wu

Ping Ding

Claude E Barberis

Eric R Goedken

Gloria Y Lo Schiavo

Philip Cox

Bin Li

Gloria Y LoSchiavo

Lily K Abbott

Xiaolei Zhang

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Indazolones as modulators of TNF signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Heterocyclic nuclear hormone receptor modulators

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

[object Object]

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thienopyridine and furopyridine kinase inhibitors

The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Triazolopyridazines

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

Growing community of inventors

Charlton, MA, United States of America

Kelly Mullen